Table 5 Open in new tab Outcomes at 3...

Outcomes	Random-effects	Heterogeneity
MACE	0.67 (0.43–1.04)	.074	57.5	0.085	.095
TLF	0.77 (0.49–1.21)	.258	43.9	0.071	.168
Death	0.96 (0.60–1.54)	.880	0	0	.557
Cardiac death	1.40 (0.71–2.77)	.328	0	0	.764
Myocardial infarction	0.51 (0.24–1.08)	.078	35.2	0.187	.214
Target lesion thrombosis	0.28 (0.06–1.18)	.082	0	0	.639
Target lesion revascularization	0.77 (0.51–1.17)	.220	0	0	.518
Target vessel revascularization	0.70 (0.48–1.01)	.054	4.3	0.015	.352

Outcomes	Random-effects	Heterogeneity
MACE	0.67 (0.43–1.04)	.074	57.5	0.085	.095
TLF	0.77 (0.49–1.21)	.258	43.9	0.071	.168
Death	0.96 (0.60–1.54)	.880	0	0	.557
Cardiac death	1.40 (0.71–2.77)	.328	0	0	.764
Myocardial infarction	0.51 (0.24–1.08)	.078	35.2	0.187	.214
Target lesion thrombosis	0.28 (0.06–1.18)	.082	0	0	.639
Target lesion revascularization	0.77 (0.51–1.17)	.220	0	0	.518
Target vessel revascularization	0.70 (0.48–1.01)	.054	4.3	0.015	.352

Table 5

Outcomes at 3 year follow-up—intention-to-treat two-stage analysis

Outcomes	Random-effects		Heterogeneity
Outcomes	HR (95% CI)	P	I²	τ²	P_Q
MACE	0.67 (0.43–1.04)	.074	57.5	0.085	.095
TLF	0.77 (0.49–1.21)	.258	43.9	0.071	.168
Death	0.96 (0.60–1.54)	.880	0	0	.557
Cardiac death	1.40 (0.71–2.77)	.328	0	0	.764
Myocardial infarction	0.51 (0.24–1.08)	.078	35.2	0.187	.214
Target lesion thrombosis	0.28 (0.06–1.18)	.082	0	0	.639
Target lesion revascularization	0.77 (0.51–1.17)	.220	0	0	.518
Target vessel revascularization	0.70 (0.48–1.01)	.054	4.3	0.015	.352

Outcomes	Random-effects		Heterogeneity
Outcomes	HR (95% CI)	P	I²	τ²	P_Q
MACE	0.67 (0.43–1.04)	.074	57.5	0.085	.095
TLF	0.77 (0.49–1.21)	.258	43.9	0.071	.168
Death	0.96 (0.60–1.54)	.880	0	0	.557
Cardiac death	1.40 (0.71–2.77)	.328	0	0	.764
Myocardial infarction	0.51 (0.24–1.08)	.078	35.2	0.187	.214
Target lesion thrombosis	0.28 (0.06–1.18)	.082	0	0	.639
Target lesion revascularization	0.77 (0.51–1.17)	.220	0	0	.518
Target vessel revascularization	0.70 (0.48–1.01)	.054	4.3	0.015	.352

Major adverse cardiac event includes all-cause death, myocardial infarction, or target vessel revascularization. Target lesion failure includes cardiac death, myocardial infarction, or target lesion revascularization.

MACE, major adverse cardiac events; TLF, target lesion failure; P_LR, log-rank test P-value; P_Q, P-value of the heterogeneity test.

This Feature Is Available To Subscribers Only